Aevius Launches With $22 Million To Make Medical Data Computable

Aevius has launched with $22 million in funding to develop artificial intelligence models that convert fragmented medical information into clinical intelligence for healthcare providers, insurers, and life sciences companies.

Insight Partners led the financing. Aevius plans to use the funding for continued model and product development, commercial deployment, and expansion of its engineering, clinical, and commercial teams.

The company is a Mass General Brigham spinout founded by Rowland Pettit, Ming Yang “Max” Lu, Faisal Mahmood, and Long Phi Le. Members of the founding team previously helped build Modella AI, which was acquired by AstraZeneca.

Aevius is applying that experience to a broader challenge involving structured, unstructured, and specialty multimodal medical data.

Creating A Computable View Of The Patient

Healthcare organizations have spent decades digitizing clinical information, but the resulting data remains distributed across different systems, formats, and medical vocabularies.

Some information is organized into structured fields, while other details are contained in physician notes, pathology reports, medical images, laboratory results, and specialty systems. Connecting those sources for research or clinical applications can require substantial manual preparation.

Aevius develops models that learn relationships across different types of medical data and across the patient’s longitudinal history.

The models create what the company describes as a refreshable multimodal patient representation. This representation is intended to provide a computable picture of a person’s clinical condition and trajectory that can be updated as additional information becomes available.

Healthcare organizations can then develop multiple applications on the same representation rather than rebuilding a data pipeline for every new question.

Possible applications include forecasting outcomes, identifying patients with clinically similar characteristics, stratifying populations, monitoring changes over time, and helping teams anticipate patient needs.

Applications Across Healthcare And Life Sciences

For health systems, Aevius expects its technology to support clinical research, care delivery, resource planning, and earlier identification of patient needs.

Health insurers could use longitudinal clinical intelligence to understand changing patient requirements and support more coordinated intervention.

Life sciences companies could apply the technology to study disease progression, evaluate treatment outcomes, identify potential biomarkers, and find patients who may meet the criteria for clinical studies.

Aevius also expects its patient representations to support AI agents. Many existing agents assemble their understanding of a patient by retrieving isolated pieces of text for each question. Aevius instead aims to give these tools access to a persistent representation grounded in a broader medical history.

The company says that approach can allow researchers, care teams, and agents to examine new questions without reconstructing the patient’s record each time.

As a spinout, Aevius combines research originating at Mass General Brigham with a leadership team experienced in commercializing medical AI. Insight Partners’ funding will support the transition from research and early development into broader commercial deployment.

KEY QUOTES:

Our mission is to make medicine computable. As a physician-scientist, I’ve worked across many types of clinical data, and there is far more knowledge in those records than we’re able to use today. We’re bringing general medical intelligence to that data, so organizations can build on a deeper understanding for their patients.

Rowland Pettit, Co-Founder and CEO of Aevius

Most AI agents today piece together their picture of a patient from text, one question at a time. We’re building a native representation of each patient’s multimodal, longitudinal history that powers prediction and analysis across an entire population. Researchers, care teams and AI agents can take on new questions without starting over, working from the whole patient rather than fragments of a record.

Ming Yang “Max” Lu, Co-Founder and Chief Technology Officer of Aevius

The value of medical AI will be measured by how well it promotes accuracy. Aevius is pursuing that goal with models grounded in the breadth and complexity of patients’ medical histories.

Eric Topol, Chair of Aevius’s Scientific Advisory Board

Mass General Brigham develops AI with the ambition to improve healthcare far beyond our own hospitals. Aevius was spun out of MGB to bring together research developed here and a team with experience taking medical AI to market. We expect that organizations throughout care delivery and life sciences will soon benefit from this powerful technology.

Chris Coburn, Chief Innovation Officer at Mass General Brigham

As with other industries, AI in healthcare is only as valuable as the data that drives it, and clinical data is among the hardest to unlock. Aevius is a rare combination of talent and technology. We are thrilled to back these inspiring founders and their vision to make medicine computable, deliver clinical intelligence to the enterprise, and ultimately improve outcomes for patients.

Dylan Morris, Managing Director at Insight Partners